FGF-HM2RA-100μg / 询价
FGF-HM2RA-500μg / 询价
FGF-HM2RA-500μgx2 / 询价
Human FGFR2 alpha (IIIb) Protein
Recombinant Human FGFR2 alpha (IIIb) Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Arg22-Glu378 [Accession | P21802-3].
The protein has a predicted MW of 66.4 kDa. Due to glycosylation, the protein migrates to 80-115 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human FGFR2 alpha (IIIb) on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human FGFR2 alpha (IIIb) is greater than 95% as determined by SEC-HPLC.
Immobilized Human FGFR2 alpha (IIIb) , hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-FGFR2 (IIIb) Antibody, hFc Tag with the EC50 of 15.2ng/ml determined by ELISA.
Four distinct genes encoding closely related FGF receptors, FGF R1 - 4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1 - 3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha isoform, or only IgII and IgIII, referred to as the beta isoform.
FGF R2a; FGFR2 alpha; KGFR; CD332; BBDS; BEK; BFR-1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; TK25; FLJ98662
(1)Katoh, Masaru. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)[J]. International Journal of Molecular Medicine, 2016.
